SVCM
OCUL icon

Saturn V Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Saturn V Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,504,880
Closed -$18.3M – 24
2025
Q4 		$18.3M Buy
1,504,880
+353,194
+31% +$4.29M 3.35% 14
2025
Q3 		$13.5M Buy
1,151,686
+423,110
+58% +$5.06M 2.95% 15
2025
Q2 		$6.76M Buy
728,576
+130,385
+22% +$1.02M 2.74% 15
2025
Q1 		$4.38M Buy
598,191
+406,735
+212% +$3.13M 2.21% 14
2024
Q4 		$1.64M Buy
+191,456
New +$1.87M 0.64% 23

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Saturn V Capital Management's OCUL Position: Q1 2026 in Review

Saturn V Capital Management sold out of Ocular Therapeutix (OCUL) in Q1 2026, closing a stake of 1,504,880 shares — an estimated $18.3M sold.

Saturn V Capital Management first reported a position in OCUL in Q4 2024 and held it in 5 quarters. The position peaked at $18.3M in Q4 2025. 271 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • Saturn V Capital Management reported no remaining Ocular Therapeutix position as of Q1 2026 after selling out during the quarter.
  • Saturn V Capital Management sold 1,504,880 Ocular Therapeutix shares in Q1 2026, an estimated $18.3M.
  • Saturn V Capital Management first reported a position in Ocular Therapeutix in Q4 2024 and held it in 5 quarters.
  • Saturn V Capital Management's Ocular Therapeutix position peaked at $18.3M in Q4 2025.
  • 271 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Saturn V Capital Management's 13F filing for Q1 2026, filed 15 May 2026.